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Abstract
The goal of brucellosis therapy is to control the illness and prevent complications,
relapses and sequelae. Important principles of brucellosis treatment include the use
of antibiotics with activity in the acidic intracellular environment (doxycycline,
rifampin), use of combination regimens and prolonged duration of treatment.
Keywords: Brucellosis, Treatment
1. Introduction
Human brucellosis is a major zoonosis caused by facultative intracellular Gram-negative
bacteria of the genus Brucella [1, 2]. Brucellosis is a systemic disease and although less lethal,
notoriously hard to eradicate, and relapses are being reported many years after the initial
infection. Since global eradication of brucellosis is due to socioeconomic and political factors,
it will not be feasible in the near future, and since the evolution of a satisfactory vaccine
for human currently seems a utopia,  there exists a need for optimal antibiotic treatment
schedules [3, 4].
The optimal treatment for brucellosis remains an unsolved medical puzzle, owing to the
propensity of the infection for relapses, the universal failure of monotherapy and the absence
of multiethnic, randomised trials evaluating possible new regimens for the disease. Current
recommended treatment regimens for brucellosis involve the use of two or more antibiotics
in order to avoid relapses occurring and to prevent prolonged use of these drugs [4, 5]. The
choice of regimen and duration of antimicrobial therapy should be based on whether focal
disease is present (e.g. endocarditis, spondylitis, meningitis, paraspinous abscesses) or there
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are underlying conditions that contraindicate certain antibiotics (e.g. pregnant patients or
children under 8 years old) [6]. In this chapter, we will discuss the effects of various antibiotic
regimens, monotherapy or in combination with other antibiotics for treating human brucel‐
losis.
1.1. General principles of therapy
Brucella spp. are facultative intracellular pathogens with a unique ability of escaping phago‐
cytosis by human macrophages. Thus, the first major parameter of successful antimicrobial
treatment of brucellosis is the use of antibiotics that penetrate into macrophages and are thus
active against the pathogen. The second important parameter is the use of antibiotics that are
active in the acidic environment of the macrophages infected with Brucella spp. [4, 7].
The third major parameter in the successful treatment of brucellosis is the use of combination
regimens, as monotherapy has universally been related to unacceptable percentages of relapse.
The identity and number of antimicrobial agents used in each combination is the one major
subject of debate on the treatment of brucellosis [4, 7].
The fourth major parameter is the evaluation of the duration of treatment, when applied
to cases of uncomplicated brucellosis. The fifth major parameter that should be taken into
account is the need for a convenient regimen for countries with poor health resources, that
is, the need for a cheap, oral regimen, and this is exactly the philosophy that prompted the
guidelines  modification  by  WHO  in  1986.  Finally,  the  sixth  major  parameter  is  the
inconcordance between in vitro studies on antimicrobial susceptibility of Brucella spp. and
in vivo efficacy or resistance [4, 7].
1.2. Therapeutic regimens
Antimicrobial therapy is useful for shortening the natural course of the disease, reducing
symptoms,  decreasing the incidence of  complications and preventing relapse.  Appropri‐
ate antibiotics should have high in vitro activity and good intracellular penetration. Thus,
the use of appropriate antibiotic combinations is required for the successful treatment of
brucellosis [1, 8].
2. Specific compounds
Historically, single-agent therapy due to the relapses after treatment has proved inadequate
for brucellosis. This is because of the primarily bacteriostatic effect exhibited by most of these
agents (predominantly tetracyclines) and to a lesser extent (or not at all) the emergence of
resistance [3].
The use of single-agent therapy with rifampin, oxytetracycline or doxycycline showed high
relapse rates of 9–25 %. The duration of therapy (either 3, 5 or 8 weeks) showed no statistically
significant difference. In addition, the use of monotherapy with trimethoprim–sulfamethoxa‐
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zole (TMP–SMX) or ciprofloxacin has led to an unacceptable relapse rate of 30 % and up to 83
%, respectively. Thus, monotherapy is not accepted as a treatment strategy for brucellosis [9].
2.1. Tetracyclines
Tetracyclines  are  the  cornerstone  of  successful  antibiotic  regimens  for  the  treatment  of
brucellosis. The two regimens suggested by WHO both include a tetracycline, and most of
the  subsequently  proposed  regimens  also  include  a  member  of  this  antibiotic  class.
Tetracyclines are inexpensive antimicrobial agents, easy to obtain and easy to adhere to;
side  effects  are  unusual  and  of  mild  severity;  and  dosage,  in  the  form  of  doxycycline
administered twice daily – the tetracycline currently employed in almost all regimens – is
convenient.  There  is  strong  evidence  that  the  tetracyclines  (especially  doxycycline  and
minocycline) are the most effective drugs for brucellosis treatment. The rate of treatment
failure in tetracyclines is 1–5 %, the relapse rate is 5–10 % and the cure rate exceeds 80 %
when an appropriate duration is used [4, 6].
Doxycycline exhibits excellent activity in the acidic phagolysosomal environment where the
compound interfaces with Brucellae, and its bactericidal activity has been repeatedly proven.
Doxycycline  has  also  been  used  as  adjunctive  monotherapy  in  cases  of  residual  focal
brucellosis  for  a  protracted  period,  although  there  are  no  official  data  supporting  its
effectiveness  when  used  as  a  single  agent  after  an  initial  combination  with  another
compound. The suggested adult dose of doxycycline employed in the various therapeutic
combinations is 100 mg b.i.d. [4, 6].
Of the other tetracyclines, minocycline has also been favoured as the tetracycline of choice in
several trials. Moreover, tigecycline is a glycylcycline antibiotic, related to tetracyclines, that
exhibits a similar but fivefold enhanced mode of action compared with tetracyclines while also
avoiding the emergence of antimicrobial resistance. The enhanced effectiveness of tigecycline
may allow for its use as a single agent in brucellosis, even with decrease in treatment duration.
Studies have shown that tigecycline can be a therapeutic alternative option for the treatment
of brucellosis [3].
2.2. Streptomycin and other aminoglycosides
Streptomycin has been the second cornerstone in the treatment of brucellosis for the last 50
years and remains a popular antibiotic choice, especially by senior specialists. The need for
parenteral administration, the significant percentage of toxicity (mainly ototoxicity) and
difficulty in obtaining the drug in certain countries are parameters responsible for a lack of
interest in the use of streptomycin in the last 25 years, especially as an acceptable all-oral
regimen had been applied in clinical practice [4, 9].
Streptomycin is an example of the discrepancy between in vitro studies and in vivo effective‐
ness, as it has been proven that the drug does not survive in the acidic phagolysosomic
environment, but it has also been proven that it is the only compound exhibiting bactericidal
activity in the first 24 h after administration. Streptomycin is usually administered at a dose
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of 15 mg/kg body weight/day for 2 or 3 weeks. Further administration would significantly
increase the rate of unwanted effects [4, 6].
The need of combining an equally effective, but less toxic, compound with doxycycline
switched interest to other members of the antibiotic class of aminoglycosides. Of these,
gentamicin is the most extensively studied compound, and various studies have proven that
its combination with doxycycline is an excellent regimen. The suggested dose is gentamicin 5
mg/kg/day, administered intravenously or intramuscularly, and the usual period of adminis‐
tration does not exceed 1 week. Netilmicin has also been employed in various combination
regimens, but it is less well studied than gentamicin [2, 4, 6].
2.3. Rifampicin
In the early 1970s, it was determined that rifampicin in combined treatment regimens is
effective for brucellosis, and by the early 1980s, this compound gradually replaced strepto‐
mycin as the complementary agent of choice to doxycycline in the treatment of the disease,
culminating in the 1986 WHO guidelines, which advocated its use in the optimal treatment of
the disease. Moreover, various therapeutic combinations have recently preferred the use of
rifampicin over doxycycline, making rifampicin the cornerstone of modern antibiotic treat‐
ment [4, 6].
Rifampicin survives in the acidic environment of  the infected macrophages and exhibits
bactericidal activity 48 h after administration. One potential problem that could arise with
the  use  of  rifampicin-containing  regimens  for  the  treatment  of  brucellosis  involves  the
concurrent  high  incidence  of  tuberculosis  in  areas  endemic  for  brucellosis,  due  to  the
pertaining  socioeconomic  status.  Fear  that  extended  use  of  rifampicin  would  increase
population resistance to the compound in the treatment of tuberculosis exists but has not
been validated in clinical practice. The suggested dose for rifampicin in the treatment of
brucellosis is 600–1200 mg/day [4, 6].
2.4. Macrolides
Ideally, macrolides should exhibit excellent efficacy against a facultative intracellular patho‐
gen, as in various other zoonotic infections and various atypical respiratory pathogens. Thus,
the newer macrolides and azithromycin, a relative compound of the class of azalides, were
considered ideal candidates for the treatment of brucellosis, in certain combination regimens.
Erythromycin was used instead of tetracycline in combination with streptomycin as early as
1961; however, the high doses necessary for achieving a clinical response similar to that of the
combination of tetracycline and streptomycin were accompanied by unacceptable high rates
of adverse reactions [4, 10].
The use of azithromycin in combination with gentamicin was also evaluated in a small clinical
trial but resulted in a disappointingly high percentage of treatment failure (either relapse, frank
failure or withdrawal due to side effects). Although the planned treatment duration was only
21 days, the cases of frank failure preclude the favourable approach to the use of azithromycin
Updates on Brucellosis174
in brucellosis. Azithromycin does not survive in the acidic environment of the infected
macrophages [4, 10].
2.5. Quinolones
The evolution of fluoroquinolones and the successful use of these compounds in various
infections, including certain zoonotic diseases and numerous intracellular pathogens, led to
the development of what amounted to a scientific obsession in proving their efficacy in the
treatment of brucellosis [4, 11].
Laboratory and clinical studies regarding using quinolone in the treatment of human brucel‐
losis suggest that there is a lack of evidence supporting the use of quinolones in the initial
therapeutic regimen. In vitro studies show that activity of quinolones decreased at pH 5
compared to pH 7 and there is lack of synergistic activity with the older antibiotics against
brucellosis. Trials with ciprofloxacin as a single agent for the treatment of brucellosis have
yielded disappointingly high percentages of treatment failure. However, recent studies with
the combination of ofloxacin and rifampicin have yielded promising results [4, 11, 12].
Newer quinolones have also been interesting candidates. A trial of moxifloxacin monotherapy
is underway in our institution. Their use in various combination regimens is promising and
should be evaluated but will eventually be hampered, as with ofloxacin and ciprofloxacin, by
cost restrictions, in the presence of a significantly more cost-effective combination regimen
such as the one advocated by WHO [1, 11].
2.6. Trimethoprim–sulfamethoxazole
Trimethoprim–sulfamethoxazole has long been a popular agent in the treatment of brucellosis
and remains the most popular choice for monotherapy trials. It has been extensively studied
in the paediatric population, and its clinical efficacy, when compared to in vitro studies of
Brucellae susceptibility, underlines the inconcordance between in vitro studies and clinical
reality. However, trimethoprim–sulfamethoxazole cannot be viewed at present as more than
a convenient third drug in a complex therapeutic regimen for focal brucellosis [4, 6].
2.7. β-Lactams
β-Lactams are active in vitro, and ampicillin was a popular therapeutic choice in the early
1950s. The in vitro susceptibility, however, does not translate to in vivo efficacy, due to the
specific in vivo environmental conditions [4, 6].
The efficacy of ceftriaxone in the treatment of a variety of infectious diseases led certain
investigators to study its possible use as a monotherapy in the treatment of brucellosis. The
results of some studies indicate failure of ceftriaxone in the treatment of acute brucellosis. There
are reports of excellent in vitro activity of cefotaxime and meropenem for treatment of
brucellosis, but these agents have not been tested clinically [4, 13].
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3. Combined regimens
Treatment of brucellosis is still far from ideal, the major problem being identification of the
most practical and affordable double or triple antimicrobial combination to prevent relapse
which is very common after treatment with single agents [13].
In 1971, the World Health Organization (WHO) suggested a 21-day regimen of tetracycline
plus streptomycin as the treatment of choice for treatment of human brucellosis. Although this
regimen was successful in reducing the early symptoms, it failed to treat the disease com‐
pletely, and immediate relapse was seen in some patients. Accordingly, in 1986, the joint Food
and Agriculture Organization of the United Nations (FAO)/WHO Expert Committee on
Brucellosis suggested two new regimens: rifampicin (600 to 900 mg/day orally) plus doxycy‐
cline (200 mg/day orally) for 6 weeks and doxycycline (200 mg/day orally) for 45 days plus
streptomycin (1 g/day intramuscularly) for 2 to 3 weeks. However, later studies showed a
treatable but high rate of relapse for the mentioned regimens [3, 5].
The rifampicin plus doxycycline regimen is the most popular treatment for brucellosis and
favourable to the more effective regimen of streptomycin plus doxycycline, possibly due to its
lower price and ease of administration. Streptomycin requires parenteral administration in a
hospital setting or in an appropriately set up primary care network. The plasma levels of
doxycycline in patients treated with rifampin were significantly lower than those in the plasma
of patients treated with doxycycline and streptomycin. Furthermore, bacterial clearance in
patients treated with rifampin was significantly higher than that in patients treated with
doxycycline and streptomycin [4, 5].
According to the suggestions of WHO, only the combination of doxycycline with gentamicin
can be considered an acceptable (albeit not ideal) novel regimen for brucellosis [3]. Giving
doxycycline plus gentamicin to people with brucellosis may reduce the incidence of total
treatment failure compared to administration of doxycycline plus streptomycin. Thus, the
combination of oral doxycycline plus gentamicin appears to be as effective as the traditional
therapy of streptomycin plus doxycycline [2, 5, 14].
A longer duration of gentamicin plus doxycycline or netilmicin plus doxycycline for at least
14 days followed by doxycycline alone for a further 30–60 days is associated with less thera‐
peutic failure and a lower relapse rate than a regimen containing aminoglycoside for only 7
days [15].
Significant geographical variations in clinical practice, even among different areas of the same
country, exist, and in general, the treatment regimen of choice reflects the traditional approach
by each institution and the clinical experience of each specialist. The combination of doxycy‐
cline for 45 days with gentamicin for the first 5–7 days is gaining acceptance as a first-line
treatment regimen, whereas multiple regimens are also applied in various countries. This is
particularly important in endemic areas, where many patients exhibit a mild form of the
disease and diagnosis and prescription can be readily made at the emergency department.
Thus, the all-oral regimen of doxycycline and rifampicin for a period of 45 days still seems a
reasonable, inexpensive and convenient first-line treatment for most endemic areas [4, 9].
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Alternative treatments for brucellosis include other antibiotics, such as fluoroquinolones and
co-trimoxazole and their combinations with rifampicin. Combinations of streptomycin with
trimethoprim–sulfamethoxazole, or rifampicin with trimethoprim–sulfamethoxazole, are
variably reported in some series [4, 16]. Some studies have suggested that fluoroquinolones in
combination with rifampin or doxycycline can be used for the treatment of acute uncompli‐
cated brucellosis as an alternative to the doxycycline plus rifampin combination [12, 13].
The use of ofloxacin plus rifampicin for the treatment of human brucellosis is as effective
as the standard doxycycline plus rifampicin regimen. Although ofloxacin in combination
with rifampicin decreased the duration of the therapy and provided shorter course of fever,
these superiorities are not sufficient for declaring this treatment as treatment of choice. The
cost  of  ofloxacin  plus  rifampicin  treatment  is  higher  than  doxycycline  plus  rifampicin
treatment [12, 17].
The use of triple antimicrobial therapy is not widely implemented except in selected situations
and in patients with focal disease. However, triple combinations, utilising trimethoprim–
sulfamethoxazole or both streptomycin and rifampicin in addition to a tetracycline, remain
popular in certain endemic regions [3, 14].
Amikacin plus doxycycline and rifampicin regimen for the treatment of human brucellosis
had a higher efficacy and more rapid action in terms of relief of symptoms compared to the
doxycycline in combination with rifampicin regimen, and no significant difference in drug
side effects and disease relapse existed in the patients of either group; adding amikacin to the
doxycycline plus rifampicin standard treatment regimen seems beneficial [18].
Nevertheless, there are still a number of obstacles to overcome, such as the need for parenteral
administration of aminoglycosides, the danger of inducing emergence of resistance to
rifampicin in countries where tuberculosis poses a problem, the treatment compliance in a
disease in which symptoms disappear a few days after initiating treatment, the difficulty of
patient follow-up in underdeveloped rural areas and the relapses, which are observed
approximately in 10 % of the patients [19].
4. Duration of treatment
Various efforts have been made to evaluate the ideal treatment duration for brucellosis; studies
with doxycycline plus an adjunct for a total duration of 30 days have yielded a higher
percentage of relapses, and the addition of gentamicin or newer quinolones, or application of
triple regimens, has not consistently exhibited an advantage or equality in the efficacy of
shorter periods of treatment. In the treatment of brucellosis, the rule is that a longer treatment
duration causes fewer relapses, and many cases with residual complaints after regimen
completion can be effectively treated with a protracted course of doxycycline alone. Many
specialists treat patients for a shorter period, but the lack of data on the geographical distri‐
bution of biotypes of Brucella melitensis and the virulence of both B. melitensis and B. abortus
and inadequate data on diagnosis and follow-up preclude any permanent conclusions. A total
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of 45 days of treatment seems to be the golden equilibrium of acceptable success, compliance
and lack of significant side effects [4, 14].
5. Special issues
Treatment protocols for brucellosis may differ in children aged less than 8 years and pregnant
women, because of adverse reactions of some medications, including inhibition of bone growth
due to tetracycline treatment in children and teratogenic potential of some drugs, such as
streptomycin [5].
Patients with localisations such as spondylitis, endocarditis, neurobrucellosis and abscess
formations in body organs may require hospitalisation for possible surgery, and triple
antibiotics (doxycycline, aminoglycoside and rifampicin) should be used for a longer period
of up to 6 months. Urgent valve replacement or drainage of abscesses may also be required
with antibiotics (Table 1) [15, 20, 21].
5.1. Paediatric population
Children often have fewer or milder symptoms than adult patients. Doxycycline and tetracy‐
cline are not recommended for children younger than 8 years of age because of irreversible
staining of permanent teeth. Thus, the use of tetracyclines in children is prohibited, and the
suggested combinations for children include rifampicin plus trimethoprim–sulfamethoxazole
or rifampicin plus streptomycin or another aminoglycoside. The preferred treatment regimen
for brucellosis in children is rifampicin plus TMP–SMZ for 6–8 weeks. An alternative regimen
is rifampicin or TMP–SMZ for 8 weeks plus gentamicin 5 mg/kg/day for the first 5 days.
Treatment over prolonged periods (>6 months) with TMP–SMZ has produced favourable
results in some cases [4, 6, 22].
5.2. Pregnancy
Among pregnant women with clinical evidence of brucellosis, high rates of spontaneous
abortion, premature delivery and intrauterine infection with foetal death have been described.
Women who received early diagnosis and adequate treatment had successful maternal and
foetal outcomes. The use of tetracyclines and streptomycin should be avoided for treatment of
human brucellosis during pregnancy. Rifampicin is the mainstay of treatment in pregnancy.
Recent reports suggest that, among antibiotic use permitted during pregnancy, there is no
superior combination with rifampicin in treatment outcome [4, 6]. TMP–SMZ should not be
used in pregnancy, either before 13 weeks because of the risk of teratogenic effects or after 36
weeks because of the risk of kernicterus [6, 23]. Furthermore, some studies indicated that
ceftriaxone/rifampicin treatment can be the most effective treatment for pregnant women with
brucellosis [24].
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5.3. Treatment of focal diseases
Focal disease in brucellosis includes endocarditis, myocarditis, pericarditis, aortic root abscess
and vertebral infection. A prolonged course of 6–52 weeks was traditionally recommended for
focal disease such as endocarditis, spondylitis or neurobrucellosis. The occurrence of focal
disease in brucellosis was reported to be epididymo-orchitis (7.5 %), meningitis (3.6 %),
endocarditis (1.5 %), bone and joint symptoms (55 %) and septic arthritis (5–10 %) [9, 25, 26].
5.3.1. Osteoarticular brucellosis and spondylitis
Osteoarticular complications of brucellosis are the most common and in cases of spondylitis,
often the most troublesome. Whereas sacroiliitis and peripheral arthritis rapidly resolve with
the administration of antibiotic regimens employed in the treatment of uncomplicated
brucellosis, spondylitis often requires protracted antibiotic administration or combined
medical and surgical treatment. Patients with focal spinal disease may have higher rates of
treatment failure if they are treated with doxycycline plus rifampicin for 6 weeks. Thus, such
patients may require a longer course of therapy for more than 5 months [4, 14, 27].
Many patients with spondylitis experience residual complaints and some have been treated
with various regimens for protracted periods, sometimes exceeding 12 months. Limited data
support the inclusion of an aminoglycoside in the treatment regimen of spondylitis patients.
Spondylitis may be the one aspect of brucellosis where quinolones may prove cost-effective;
their ability to penetrate and achieve significant concentrations in bone and soft tissues allows
their use in brucellar spondylitis for maximising response. An initial report of a combination
of doxycycline and ciprofloxacin for a period of 3 months has been encouraging [4, 14, 28].
5.3.2. Brucella endocarditis
Brucella endocarditis is another ominous, but fortunately extremely rare, complication (2–5
%). As a rule, brucellar endocarditis is treated surgically, and the duration of postsurgical
antibiotic treatment ranges 3–15 months, usually utilising at least three of the active com‐
pounds against brucellosis [4, 14].
Cases of isolated conservative treatment of brucellar endocarditis exist, and conservative
treatment can be considered an option in the absence of prosthetic valves, the absence of
congestive heart failure and the presence of only mild extravalvular heart involvement and
assuming that antibiotic administration starts immediately after diagnosis [4, 14]. Most
patients with brucellar endocarditis are usually treated with the use of a combination of
tetracycline and doxycycline, rifampin and an aminoglycoside or TMP–SMX for a mean
duration of 3 months. Surgical interventions are more likely to be required for treatment of
patients with heart failure, valvular destruction and abscesses [9, 14].
5.4. Chronic brucellosis
There is no consensus on the definition of chronic brucellosis, and thus, there is no background
for establishing guidelines for treatment. Protracted courses of the usual regimens should be
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advocated, but treatment options are largely subject to specialist preferences and individual‐
ised patient parameters. One important aspect of the so-called chronic brucellosis is the
possibility of an underlying immune-mediated mechanism in its pathogenesis: numerous
anecdotal reports of the use of corticosteroids in patients with ‘chronic’ brucellosis exist but
cannot be substantiated. Others suggest that the clinical entity that is characterised as chronic
brucellosis is in fact a result of impaired cellular immunity; thus, the use of interferon has been
advocated, but this approach cannot be substantiated either [4, 6].
Patient group Recommended therapy Alternative therapy
Acute brucellosis (adults and
children "/>8 years old)
Doxycycline 100 mg PO twice daily for 45
days plus either streptomycin 15 mg/kg IM
daily for 14–21 days, gentamicin 3–5 mg/kg
IV or IM daily for 7–14 days or doxycycline
100 mg PO twice daily for 45 days plus
rifampicin 600–900 mg PO daily for 45 days
Rifampicin 600 mg PO daily for 42 days
plus quinolone (ofloxacin 400 mg PO
twice daily or ciprofloxacin 750 mg PO
twice daily) for 42 days or doxycycline
100 mg PO twice daily plus TMP–SMZ
one double-strength tablet twice daily
for 2 months or monotherapy with
doxycycline or minocycline PO daily
for 6–8 weeks
Children <8 years old TMP–SMZ 5 mg/kg (of trimethoprim
component) PO twice daily for 45 days plus
gentamicin 5–6 mg/kg IV daily for 7 days or
rifampicin 15 mg/kg PO daily for 45 days
plus gentamicin 5–6 mg/kg IV or IM daily for
7 days
Brucellosis during pregnancy Rifampicin 600–900 mg PO daily for 45 days Rifampicin 600 mg PO daily for 45 days
plus TMP–SMZ one double- strength
tablet twice daily for 45 days
Focal infections (endocarditis,
spondylitis, meningitis,
paraspinous abscesses)b
Doxycycline 100 mg PO twice daily and
rifampicin 600 mg PO daily for 6–52 weeks
plus either streptomycin 1 g IM daily or
gentamicin 3–5 mg/kg IV or IM daily for 14–
21 days
Consider TMP–SMZ, ciprofloxacin 750
mg PO twice daily or ofloxacin
400 mg PO twice daily as a substitute
for doxycycline or rifampicin
IM, intramuscularly; IV intravenously; PO, orally; TMP–SMZ, trimethoprim–sulfamethoxazole
aThe choice of regimen/duration should be based on the presence of focal disease and whether there are underlying
conditions that may contraindicate certain antibiotic therapy. Aminoglycoside and quinolone dosage should be adjusted
in patients with poor renal function.
bPatients with focal disease, such as spondylitis or endocarditis, may require long courses of therapy depending on the
clinical evolution. Surgery should be considered for patients with endocarditis, cerebral or epidural abscess, spleen or
hepatic abscess or other abscesses that are antibiotic resistant.
Table 1. Recommended treatment for brucellosis according to patient groupa
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6. Future targets
6.1. Re-evaluating current alternatives
Because the current officially endorsed regimens are not ideal, other approaches using
currently existing antibiotics should be further validated. Gentamicin has been recently
validated in a large sample with excellent results, yet its parenteral administration does not
service the requested convenience, and the agent should be further evaluated only for seriously
complicated, hospitalisation-requiring cases. On the other hand, co-trimoxazole-containing
regimens can be considered as convenient (all-oral) regimens that may be of significantly lower
cost than traditional combinations in certain developing countries. The emergence of com‐
munity-acquired resistance should be studied for rifampicin; its potential overuse/abuse may
reflect on increasing rifampicin resistance in Mycobacterium tuberculosis because both brucel‐
losis and tuberculosis can simultaneously be endemic/exist in the same countries in many parts
of the world [4, 7].
6.2. Optimising antibiotic delivery
An interesting new approach, still in preclinical evaluation, is the optimisation of antibiotic
delivery in the macrophages by using antibiotic-containing microparticles. The development
of gentamicin-loaded poly-(D,L-lactide-co-glycolide) (PLGA) microspheres and studies of
their release patterns are promising in this field because optimisation of encapsulation
efficiency and gentamicin loading may lead to prolonged antibiotic release. Gentamicin-
containing PLGA microspheres can be successfully phagocytosed by infected THP-1 human
monocytes, and the antibiotic reaches Brucella-specific compartments and reduces the intra‐
cellular Brucella infection [7, 14].
6.3. Novel compounds
Following development, many agents have generated hope as a possible monotherapeutic
treatment of human brucellosis with most of these hopes proving to be futile in clinical practice.
Most of these new agents are costly, intravenously administered antibiotics that would be
neither practical nor cost-effective for the disease. There is one new agent that is unique enough
to generate theoretical interest of its possible future role in brucellosis treatment. Tigecycline
is a novel glycylcycline antibiotic, a 9-t-butylglycylamido minocycline, which inhibits bacterial
protein synthesis with 3- and 20-fold greater potency than that of minocycline and tetracycline,
respectively, partly attributed to its binding to additional ribosomal subunit targets. Tetracy‐
clines are the mainstay of most antibiotic regimens for brucellosis, and replacing doxycycline
with a more potent analogue might not only increase efficacy but might offer further advan‐
tages by possibly reducing treatment duration [7, 14].
7. Conclusion
Brucellosis, the most common bacterial zoonosis in the world, is still endemic in many
developing countries. The optimal duration of antibiotic treatment in patients with brucellosis
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is unclear, even for the most common clinical presentation of acute, uncomplicated brucellosis
without focal disease [4, 6].
Most cases with uncomplicated brucellosis in adults can be readily treated with the combina‐
tion of doxycycline and rifampicin (in a dose adjusted to body weight) for 45 days. The use of
doxycycline for 45 days in combination with streptomycin for 14 days (or gentamicin for 5–7
days) is a reasonable alternative approach. For patients with treatment failure or repeated
relapses, an array of second-line agents, such as quinolones, or trimethoprim-sulfamethoxa‐
zole can be utilised [4, 14].
For patients with complicated disease, therapeutic intervention demands a careful evaluation
of the patient and a thorough therapeutic plan. Patients with spondylitis should possibly
receive a quinolone in the initial regimen, for a protracted period [4, 14].
Attempts at monotherapy should be reserved for therapeutic trials or cases where traditional
therapeutic regimens have failed. Chronic brucellosis should be ideally classified as a clinical
entity and treated for a protracted period with one of the accepted regimens [4, 6].
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